Table 1.
Baseline patient demographics and clinical characteristics by treatment group
| Demographics |
GSK2982772 60 mg b.i.d. (N = 23) |
GSK2982772 60 mg t.i.d. (N = 24) |
Placebo b.i.d. (N = 10) |
Placebo t.i.d. (N = 8) | Total (N = 65) |
|---|---|---|---|---|---|
| Age in years (mean (SD)) a | 44.6 (12.52) | 47.5 (13.41) | 40.2 (15.98) | 55.6 (7.98) | 46.3 (13.40) |
| Sex (n (%)) | |||||
| Female | 6 (26) | 5 (21) | 3 (30) | 2 (25) | 16 (25) |
| Male | 17 (74) | 19 (79) | 7 (70) | 6 (75) | 49 (75) |
| BMI (kg/m2) (mean (SD)) | 28.22 (4.381) | 29.46 (3.110) | 28.52 (5.350) | 29.21 (3.293) | 28.85 (3.950) |
| Ethnicity (n (%)) | |||||
| Hispanic or Latino | 0 | 3 (13) | 0 | 0 | 3 (5) |
| Not Hispanic or Latino | 23 (100) | 21 (88) | 10 (100) | 8 (100) | 62 (95) |
| Race detail | |||||
| Asian/Native Hawaiian/other Pacific Islander | 3 (12) | 4 (16) | 2 (20) | 2 (13) | 11 (18) |
| White ‐ Arabic/North African heritage | 1 (4) | 1 (4) | 1 (10) | 0 | 3 (5) |
| White ‐ White/Caucasian/European heritage | 19 (83) | 19 (79) | 7 (70) | 6 (75) | 51 (78) |
| Body surface area (%) (mean (SD)) | 9.8 (9.94) | 10.3 (11.33) | 8.5 (9.10) | 5.1 (1.13) | 9.2 (9.73) |
| Duration in years (mean (SD)) | 16.9 (11.12) | 18.5 (12.58) | 14.3 (11.79) | 21.0 (14.89) | 17.6 (12.12) |
| Prior treatment (n (%)) | |||||
| Yes | 23 (100) | 24 (100) | 9 (90) | 8 (100) | 64 (98) |
| No | 0 | 0 | 1 (10) | 0 | 1 (2) |
| Naïve to phototherapy (n (%)) | |||||
| Yes | 6 (26) | 7 (29) | 4 (40) | 2 (25) | 19 (29) |
| No | 17 (74) | 17 (71) | 6 (60) | 6 (75) | 46 (71) |
| PASI (mean (SD)) | 10.3 (5.61) | 10.3 (6.11) | 8.4 (5.18) | 7.8 (2.87) | 9.7 (5.47) |
| Index lesion PLSS score (mean (SD)) | 8.1 (1.62) | 7.5 (1.44) | 6.9 (1.73) | 8.5 (1.51) | 7.7 (1.61) |
| Median (min‐max) | 8.0 (5–11) | 8.0 (5–11) | 6.0 (5–10) | 8.5 (7–11) | 7.0 (5–11) |
| Index lesion severity area (cm2) (mean (SD)) | 57.5 (50.01) | 68.9 (109.10) | 50.6 (35.41) | 67.3 (81.60) | 61.9 (78.04) |
| Biopsy lesion PLSS score (mean (SD)) | 7.5 (1.56) | 7.5 (1.41) | 6.7 (1.34) | 8.5 (1.51) | 7.5 (1.51) |
| Median (min‐max) | 7.0 (5–11) | 7.0 (5–11) | 6.5 (5–9) | 8.5 (7–11) | 7.0 (5–9) |
| Biopsy lesion severity area (cm2) (mean (SD)) | 84.1 (116.79) | 57.3 (61.93) | 54.9 (50.28) | 67.5 (120.80) | 67.7 (90.45) |
| PGA score (mean (SD)) | 3.4 (0.59) | 3.3 (0.48) | 3.3 (0.67) | 3.5 (0.53) | 3.4 (0.55) |
| History of tobacco use (n (%)) | |||||
| Never smoked | 8 (35) | 7 (29) | 4 (40) | 2 (25) | 21 (32) |
| Current smoker | 10 (43) | 8 (33) | 3 (30) | 2 (25) | 23 (35) |
| Former smoker | 5 (22) | 9 (38) | 3 (30) | 4 (50) | 21 (32) |
b.i.d., twice daily; BMI, body mass index; min, minimum; max, maximum; PASI, Psoriasis Area Severity Index; PGA, Physician Global Assessment; PLSS, Psoriatic Lesion Severity Sum; SD, standard deviation; t.i.d., three times daily.
a
Age is imputed when full date of birth is not provided.